Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall celebrexCelebrex heart attack and stroke risks were announced by Pfizer, this blockbuster drug''s maker, in December 2004. A study conducted by the National Cancer Institute in over 100 medical centers nationwide was suspended after preliminary evidence suggested that patients taking 400 and 800 milligram doses were two to four times more likely to suffer Celebrex heart attack and stroke events than trial participants who had been taking a placebo pill. These potential Celebrex heart attack and stoke risks have prompted a major investigation of this pain medication''s effect on long term cardiovascular safety.
Celebrex is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID) that has been available in the United States since 1999. Until recent news of Celebrex heart attack risks, Celebrex had a relatively strong safety record and was the tenth most popular drug prescribed to patients suffering from arthritis and other chronic pain conditions.
Since the announcement of potential Celebrex heart complications, new prescription sales have dropped fifty-six percent in less than one month. Pfizer has agreed to pull all television advertisements for Celebrex until the threat of Celebrex heart side effects is adequately assessed. The FDA has suggested that doctors and patients consider alternative treatments that are not known to carry the same Celebrex heart attack and stroke risks.
News of possible Celebrex heart attack and stoke risks follows a series of studies indicating that all COX-2 selective NSAIDs may pose serious cardiovascular risks. Vioxx, a once popular selective NSAID, was voluntarily pulled off the market in September 2004 after clinical trials found that patients taking Vioxx for more than eighteen months were twice as likely to suffer adverse cardiovascular events.
Bextra clinical trials also indicate cardiovascular risks similar to Celebrex heart complications for certain patient populations. Naproxen, an original non-selective NSAID that has been on the market for almost thirty years, has also recently been shown to cause elevated cardiovascular risks.
The National Institutes of Health has ordered the review of forty agency sponsored clinical trials in order to further assess Celebrex heart attack and stroke risks. Some prominent research universities across the nation are also restructuring their Celebrex clinical trials in light of potential Celebrex heart risks. Pfizer has made no indication of their plans to pull Celebrex off the market despite potential Celebrex heart and stroke risks.
If you or a loved one is currently taking Celebrex, and you are concerned about potential Celebrex heart attack and stoke risks, you should first speak to your health care professional before making any changes to your treatment regiment. Your doctor can consider the risks and benefits associated with your Celebrex use in order to determine if an alternative treatment would be safer. You may also wish to contact a legal professional who can advise you of your legal rights and options in a Celebrex heart case.
After COX-2 painkillers – Vioxx, Celebrex and Bextra- came under scrutiny when cardiovascular risks were associated to the drugs some drugmakers saw this as an opportunity to try to capitalize on the events.
Vioxx went off the market in Se...
Merck & Co. and Pfizer Inc. have been criticized for their aggressive marketing campaigns for its COX-2 drugs, putting scrutiny on pharmaceutical advertising as a whole. Between December 2003 and November 2004, pharmaceutical ad spending increased 30...
A three-day FDA Advisory Committee meeting has wrapped, but the COX-2 drugs controversy is still not resolved. Although the panel of government medical experts advised keeping the drugs, including Pfizer Inc.’s Celebrex and Bextra, on the market, new...